Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VisionHD
- Development stage
- Unknown
- Lead developer
- Voyageur Pharmaceuticals
- Administration
- Oral
01
Overview
VisionHD is a Voyageur Pharmaceuticals high-density barium sulfate powder for reconstitution as an oral suspension. It is a diagnostic radiographic contrast agent indicated for double-contrast examinations of the esophagus, stomach, and duodenum, and for visualization of the gastrointestinal tract during conventional X-ray and computed tomography procedures in patients aged 12 years and older. Barium sulfate is not systemically absorbed to a meaningful extent; it provides contrast by physically attenuating X-rays within the gastrointestinal lumen.
- Brand names
- VisionHD
Beyond the preview
Go deeper on VisionHD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VisionHD.